Evidence map›Paper›PMID 29876741›Full record

ReviewWorld journal of pediatrics : WJP2018

Two novel mutations in the GAN gene causing giant axonal neuropathy.

Monica Irad Normendez-Martínez, Lucero Monterde-Cruz, Roberto Martínez, Magdalena Marquez-Harper, Nayelli Esquitin-Garduño, Margarita Valdes-Flores, Leonora Casas-Avila, Valeria Ponce de Leon-Suarez, Viktor Javier Romero-Díaz, Alberto Hidalgo-Bravo

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in World journal of pediatrics : WJP, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.8field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Gigaxonin is required for intermediate filament transport.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Monica Irad Normendez-MartínezMedical Specialties Hospital, Boulevard Milenio 130, San Carlos la Roncha, 37660, Leon, Guanajuato, Mexico.
Lucero Monterde-CruzDepartment of Genetics, National Institute of Rehabilitation, Avenue Mexico-Xochimilco 289, 14389, Mexico City, Mexico.
Roberto MartínezMedical Specialties Hospital, Boulevard Milenio 130, San Carlos la Roncha, 37660, Leon, Guanajuato, Mexico.
Magdalena Marquez-HarperMedical Specialties Hospital, Boulevard Milenio 130, San Carlos la Roncha, 37660, Leon, Guanajuato, Mexico.
Nayelli Esquitin-GarduñoMedical Specialties Hospital, Boulevard Milenio 130, San Carlos la Roncha, 37660, Leon, Guanajuato, Mexico.
Margarita Valdes-FloresDepartment of Genetics, National Institute of Rehabilitation, Avenue Mexico-Xochimilco 289, 14389, Mexico City, Mexico.
Leonora Casas-AvilaDepartment of Genetics, National Institute of Rehabilitation, Avenue Mexico-Xochimilco 289, 14389, Mexico City, Mexico.
Valeria Ponce de Leon-SuarezDepartment of Genetics, National Institute of Rehabilitation, Avenue Mexico-Xochimilco 289, 14389, Mexico City, Mexico.
Viktor Javier Romero-DíazDepartment of Histology, School of Medicine, Autonomous University of the State of Nuevo Leon, Monterrey, Mexico.
Alberto Hidalgo-BravoMedical Specialties Hospital, Boulevard Milenio 130, San Carlos la Roncha, 37660, Leon, Guanajuato, Mexico. ahidalgo@inr.gob.mx.
Instituto Nacional de Rehabilitación · MXUniversidad Autónoma de Nuevo León · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGiant axonal neuropathy (GAN) is a rare neurodegenerative disease transmitted in an autosomal recessive mode. This disorder presents motor and sensitive symptoms with an onset in early childhood. Progressive neurodegeneration makes the patients wheelchair dependent by the end of the second decade of life. Affected individuals do not survive beyond the third decade of life. Molecular analysis has identified mutations in the gene GAN in patients with this disorder. This gene produces a protein called gigaxonin which is presumably involved in protein degradation via the ubiquitin-proteasome system. However, the underlying molecular mechanism is not clearly understood yet.

methodsHere we present the first patient from Mexico with clinical data suggesting GAN. Sequencing of the GAN gene was carried out. Changes in the nucleotide sequence were investigated for their possible impact on protein function and structure using the publicly available prediction tools PolyPhen-2 and PANTHER.

resultsThe patient is a compound heterozygous carrying two novel mutations in the GAN gene. The sequence analysis revealed two missense mutations in the Kelch repeats domain. In one allele, a C>T transition was found in exon 9 at the nucleotide position 55393 (g.55393C>T). In the other allele, a transversion G>T in exon 11 at the nucleotide position 67471 (g.67471G>T) was observed. Both of the bioinformatic tools predicted that these amino acid substitutions would have a negative impact on gigaxonin's function.

conclusionThis work provides useful information for health professionals and expands the spectrum of disease-causing mutations in the GAN gene and it is the first documented case in Mexican population.

Indexed as

Genetic Predisposition to DiseaseBiopsy, NeedleChildCytoskeletal ProteinsDisease ProgressionElectromyographyFemaleGiant Axonal NeuropathyHumansImmunohistochemistryMexicoMutation, MissenseRare DiseasesRisk AssessmentCytoskeletal ProteinsGAN protein, humanGANGeneticsGiant axonal neuropathyIncapacityNeurodegenerative

Identifiers

PMID29876741
OpenAlexW2805445870

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.